Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Status:
Completed
Trial end date:
2018-08-06
Target enrollment:
Participant gender:
Summary
Background:
- Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system that
progressively weakens and destroys the pathways of the nervous system. About 10 percent
to 15 percent of patients develop primary-progressive MS (PP-MS), characterized by
progressive accumulation of disability from the disease onset, without any marked
improvements or relapses. There are currently no effective treatments for PP-MS.
- Idebenone is a manmade drug that is similar to a naturally occurring compound known as
coenzyme Q10, a common dietary supplement. Research data suggest that idebenone may be
able to limit demyelination and death of brain cells and thereby slow or halt the
progression of neurological dysfunction such as that occurring in MS.
Objectives:
- To evaluate the safety and effectiveness of using idebenone to treat primary progressive
MS.
Eligibility:
- Individuals between 18 and 65 years of age who have been diagnosed with primary progressive
multiple sclerosis.
Design:
- The study will last 3 years and will be divided into two parts: a 1-year pretreatment
baseline and 2 years of treatment with either idebenone or a placebo.
- Pre-treatment study: approximately 5 clinic visits over 1 year.
- Visit 1: Comprehensive medical history and neurological examination, with brain scans
and neurological tests.
- Visit 2: Magnetic resonance imaging (MRI) scan of the spine and lymphocytapheresis
(withdrawal of white blood cells for testing).
- Visit 3: Lumbar puncture.
- Visit 4: Skin biopsy.
- Visit 5: Repeat MRI of the brain and spinal cord, as well as neurological tests; these
tests will be scheduled over 2 days.
- After the five pretreatment visits, patients will receive a 6-month supply of study
medication (either idebenone or a placebo) to take three times a day with food
- Patients will continue to have regular followup clinic visits with brain MRI scans,
blood tests, and other evaluations of brain and nervous system function. Randomly
selected participants will have additional MRI scans for further safety precautions.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Neurological Disorders and Stroke (NINDS)